Doebele R, et al. Efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC). IASLC 2018; abstract OA02.01.
Behandeling stadium II-III niet-kleincellig longcarcinoom gaat flink op de schop
apr 2024 | Immuuntherapie, Longoncologie